Phenylephrine

Last updated

Phenylephrine
Phenylephrine Structural Formula V1.svg
(R)-Phenylephrine molecule ball.png
Clinical data
Pronunciation /ˌfɛnəlˈɛfriːn,fiː-,-ɪn/
Trade names Neosynephrine, Sudafed PE, others [1] [2] [3] [4]
Other namesPhenephrine; Fenefrine; L-m-Synephrine; Metaoxedrine; Neo-Oxedrine; Mesatonum; Neosynephrine; Adrianol; (R)-β,3-Dihydroxy-N-methylphenethylamine [1] [2] [4]
AHFS/Drugs.com Monograph
License data
Routes of
administration 		By mouth, intranasal, ophthalmic, intravenous, intramuscular, rectal [5] [6] [7]
Drug class α1-adrenergic receptor agonist; vasopressor
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability Oral: conflicting—38% [8] [3] [9] [10] or 0.003% [11]
Protein binding 95%[ citation needed ]
Metabolism Liver and intestines (via oxidative deamination by MAO-A and MAO-B; sulfation; glucuronidation) [5] [8] [3] [11] [9]
Metabolites • meta-Hydroxymandelic acid [9] [3]
• Sulfate conjugates [9] [3]
• Glucuronide conjugates [9]
Onset of action IV: Very rapid [12]
Oral: 15–20 min [12] [9]
Intranasal: <2 min [9]
Eye drop: <30 min [9]
Elimination half-life 2–3 hours [8] [5] [3] [13]
Duration of action IV: 20 min–5 h [12] [9]
Oral: 2–4 h [12] [9]
Intranasal: 0.5–4 h [9]
Eye drop: 3–7 h [9]
Excretion Urine: 86% (3–16% unchanged) [5] [8] [3]
Identifiers
  • 3-[(1R)-1-Hydroxy-2-(methylamino)ethyl]phenol
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.000.386 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C9H13NO2
Molar mass 167.208 g·mol−1
3D model (JSmol)
  • O[C@H](c1cc(O)ccc1)CNC
  • InChI=1S/C9H13NO2/c1-10-6-9(12)7-3-2-4-8(11)5-7/h2-5,9-12H,6H2,1H3/t9-/m0/s1 Yes check.svgY
  • Key:SONNWYBIRXJNDC-VIFPVBQESA-N Yes check.svgY
   (verify)

Phenylephrine, sold under the brand names Neosynephrine and Sudafed PE among others, is a medication used as a decongestant for uncomplicated nasal congestion in the form of a nasal spray or oral tablet, [5] to dilate the pupil, to increase blood pressure given intravenously in cases of low blood pressure, and to relieve hemorrhoids as a suppository. [12] [14] It can also be applied to the skin. [12] [5]

Contents

Common side effects when taken by mouth or injected include nausea, vomiting, headache, and anxiety. [12] Use on hemorrhoids is generally well tolerated. [12] Severe side effects may include a slow heart rate, intestinal ischemia, chest pain, kidney failure, and tissue death at the site of injection. [12] [14] It is unclear whether its use during pregnancy and breastfeeding is safe. [12] Phenylephrine is a selective α1-adrenergic receptor agonist with minimal to no β-adrenergic receptor agonist activity or induction of norepinephrine release. [5] [8] [15] It causes constriction of both arteries and veins. [12]

Phenylephrine was patented in 1933 [16] and came into medical use in 1938. [17] It is available as a generic medication. [14] [18] [19] Unlike pseudoephedrine, abuse of phenylephrine is very uncommon. [20] Its effectiveness as a nasal decongestant has been questioned. [12] [21] [22] In 2023, a U.S. Food and Drug Administration (FDA) panel concluded that the drug was ineffective as a nasal decongestant when taken orally. [23] In November 2024, the FDA proposed to remove oral phenylephrine as an active ingredient that can be used in over-the-counter (OTC) monograph drug products for the temporary relief of nasal congestion. [24] This decision was made when it was found that phenylephrine as a decongestant performs no better than placebo.

Medical uses

Decongestant

Phenylephrine is used as an alternative to pseudoephedrine as a decongestant, whose availability has been restricted in some countries due to a potential for use in the illicit synthesis of methamphetamine. [25] Its efficacy as an oral decongestant has been questioned, with several independent studies finding that it provided no more relief to sinus congestion than a placebo. [26] [27] [28]

A 2007 meta-analysis concluded that the evidence for its effectiveness is insufficient, [29] though another meta-analysis published shortly thereafter by researchers from GlaxoSmithKline found the standard 10-mg dose to be more effective than a placebo; however, the fact that GSK markets many products containing phenylephrine has raised some speculation regarding selective publishing and other controversial techniques. [30] A 2007 study by Wyeth Consumer Healthcare notes that 7 studies available in 1976 support the efficacy of phenylephrine at a 10 mg dosage. [31] The Food and Drug Administration withdrew the indication "for the temporary relief of nasal congestion associated with sinusitis" in 2007. [12]

Two studies published in 2009, examined the effects of phenylephrine on symptoms of allergic rhinitis by exposing people to pollen in a controlled, indoor environment. Neither study was able to distinguish between the effects of phenylephrine or a placebo. Pseudoephedrine and loratadine–montelukast therapy were found to be significantly more effective than both phenylephrine and placebo. [26] [27]

Pseudoephedrine was previously much more commonly available in the United States, however, provisions of the Combat Methamphetamine Epidemic Act of 2005 placed restrictions on the sale in the United States of pseudoephedrine products to prevent the clandestine manufacture of methamphetamine. Since 2004, phenylephrine has been increasingly marketed as a substitute for pseudoephedrine; some manufacturers have changed the active ingredients of products to avoid restrictions on sales. [32] Phenylephrine has been off-patent for some time,[ when? ] and many generic brands are available.[ citation needed ]

In September 2023, an independent advisory committee to the U.S. Food and Drug Administration (FDA) unanimously agreed that there is insufficient evidence showing that "orally administered phenylephrine is effective as a nasal decongestant". [33] The committee also unanimously believes that this does not need further study. The FDA responded to the committee, stating it would take its advice under advisement. [23] [34] In November 2024, the FDA proposed to remove oral phenylephrine as an active ingredient that can be used in over-the-counter (OTC) monograph drug products for the temporary relief of nasal congestion. [24]

Hemorrhoids

Hemorrhoids are caused by swollen veins in the rectal area. [35] Phenylephrine can be used topically to prevent symptoms of hemorrhoids. Phenylephrine causes the constriction of vascular smooth muscle and is often used in the treatment of hemorrhoids to narrow the swollen veins and relieve the attendant pain. However, veins contain less vascular smooth muscle in their walls than arteries. Products for treatment may also include substances that will form a protective barrier over the inflamed area, resulting in less pain when feces are passed. [36]

Phenylephrine hydrochloride at 0.25% is used as a vasoconstrictor in suppository formulations for hemorrhoid treatment. [37]

Pupil dilation

Phenylephrine is used as an eye drop to dilate the pupil to facilitate visualization of the retina. It is often used in combination with tropicamide as a synergist when tropicamide alone is not sufficient. Narrow-angle glaucoma is a contraindication to phenylephrine use. As a mydriatic, it is available in 2.5% and 10% eye drops. Phenylephrine eye drops are applied to the eye after a topical anesthetic is applied. [38]

Intraocular bleeding

Phenylephrine has been used as an intracameral injection into the anterior chamber of the eye to arrest intraocular bleeding occurring during cataract and glaucoma surgery. [39]

Low blood pressure

Phenylephrine is commonly used as a vasopressor to increase the blood pressure in unstable patients with hypotension (low blood pressure), especially resulting from septic shock. [40] [41] Such use is common in surgery and anesthesia or critical-care practices; [40] [41] it is especially useful in counteracting the hypotensive effect of epidural and spinal anesthesia, as well as the vasodilating effect of bacterial toxins and the inflammatory response in sepsis and systemic inflammatory response syndrome.

Because of its vasoconstrictive effect, phenylephrine can cause severe necrosis if it infiltrates the surrounding tissues. Because of this, it should be given through a central line if at all possible. Damage may be prevented or mitigated by infiltrating the tissue with the alpha-blocker phentolamine by subcutaneous injection. [42]

In clinical studies, phenylephrine, administered intravenously, increases blood pressure, decreases cardiac output, increases cerebral blood flow, and decreases cerebral tissue oxygen saturation. [40] [41] The decreases in cardiac output, increases in cerebral blood flow, and decreases in cerebral tissue oxygen saturation with phenylephrine are all related to the degree of blood pressure increase. [40] The decrease in cardiac output is primarily due to a decrease in heart rate and a modest decrease in stroke volume. [40] The decrease in heart rate is due to activation of the arterial baroreflex, which regulates heart rate in response to changes in blood pressure. [40] [41] Because of the decrease in cardiac output, phenylephrine is a negative inotropic agent. [40] Its effects on cardiac output and cerebral oxygenation are unfavorable, and on account of this, the use of phenylephrine in the treatment of intraoperative hypotension is now being recommended against and moved away from in favor of other agents without these adverse effects like ephedrine and dopamine. [40] [41]

When taken orally, phenylephrine has a threshold dose of about 50 mg to affect the cardiovascular system, a dose at which the drug decreases heart rate and slightly increases arterial blood pressure. [8] Additionally, an over-the-counter dose of 60 mg produces a slight increase in heart rate with no detectable changes in blood pressure. [8] However, other literature reports that doses over 15 mg affect the cardiovascular system, including increases in blood pressure and decreases in heart rate. [11] Higher doses, like 150 mg, more robustly affect the cardiovascular system. [9]

Other uses

Phenylephrine has been used in the treatment of postural orthostatic tachycardia syndrome (POTS). [43] It has been found to improve vascular resistance, enhance circulatory support, and improve symptoms of orthostatic intolerance in people with the condition. [43] It has been described as particularly effective in people with neuropathic POTS. [43] However, phenylephrine has not been specifically approved for the treatment of POTS and data on this use are limited. [43] This is also the case with other medications used in the treatment of POTS. [43]

Phenylephrine has been used in the treatment of priapism. [44] [45]

Available forms

Phenylephrine is available in the form of oral tablets and syrups for use as a nasal decongestant, as an intravenous solution to treat hypotension, as an ophthalmic solution, spray, or eye drop to cause pupil dilation, and as a cocoa butter suppository, among other forms. [6] [7] It was also previously available as a metered aerosol for inhalation, but this formulation was discontinued. [6]

Phenylephrine is available both alone and in combination with other drugs. [6] [7] These other drugs include antihistamines like chlorpheniramine, doxylamine, promethazine, and mepyramine (pyrilamine); analgesics like paracetamol (acetaminophen), ibuprofen, ketorolac, and codeine; cough suppressants like dextromethorphan; expectorants like guiafenesin; anticholinergics like cyclopentolate and tropicamide; and β-adrenergic receptor agonists like isoprenaline (isoproterenol). [6] [7] It is used in combination with antihistamines and analgesics in cough and cold preparations, with anticholinergics in ophthalmic formulations, and with β-adrenergic receptor agonists in inhalational forms. [6] [7] Intravenous phenylephrine is always formulated by itself. [6]

Contraindications

Phenylephrine is contraindicated in people with hypertension, hyperthyroidism, and heart disease due to its vasoconstrictor effects. [8] Relative contraindications include people with Raynaud's syndrome due to vasoconstriction, those taking monoamine oxidase inhibitors (MAOIs) due to inhibition of the metabolism of phenylephrine, and people with prostate problems due to potential exacerbation of urinary retention. [8] [46]

Side effects

Phenylephrine taken orally at indicated doses is usually well-tolerated. [11] It may cause side effects such as headache, reflex bradycardia, excitability, restlessness, and cardiac arrhythmias. [12] At higher than indicated doses, phenylephrine can increase blood pressure and decrease heart rate. [11] A 45 mg dose of phenylephrine can increase systolic blood pressure by 20 mmHg. [11] Possible side effects of intravenous phenylephrine are dose-dependent and may include bradycardia and reactive hypertension. [11]

Heart

The primary side effect of phenylephrine is high blood pressure. People with high blood pressure are typically advised to avoid products containing it. Because this medication is a sympathomimetic amine without β-adrenergic receptor agonist activity, it does not increase contractility force and output of the cardiac muscle. It may increase blood pressure resulting in a slow heart rate through stimulation of vascular (likely carotid) baroreceptors. A common side effect during IV administration is reflex bradycardia. [47] The low concentration eye drops do not cause blood pressure changes and the changes with the higher dose drops do not last long. [48]

The cardiovascular effects of phenylephrine may be potentiated in people with hypertension. [11] Hypertensive crisis with phenylephrine eye drops has been reported in people with hypertension. [11] In people with underlying cardiovascular disease, phenylephrine has been found to increase blood pressure and cause associated impairment in myocardial perfusion. [11] Other reported side effects of phenylephrine have included increased blood pressure, vasoconstriction resulting in worsened orthostatic tolerance, atrial fibrillation following coronary artery bypass surgery, decreased cerebral oxygenation, bradycardia in people with spinal cord injury, cardiac arrhythmias, pulmonary edema, myocardial infarction, and microvascular occlusion syndrome. [11] Rarely, stroke has been reported with phenylephrine, including in the oral, topical, and intravenous forms. [11]

Due to the increased risk of side effects in people with hypertension, phenylephrine is not suggested for use in this population. [49] [8]

Others

Prostatic hyperplasia can also be worsened by use, and chronic use can lead to rebound hyperemia. [50] People with a history of anxiety or panic disorders, or on anticonvulsant medication for epilepsy should not take this substance. The drug interaction might produce seizures. Some patients have been shown to have an upset stomach, severe abdominal cramping, and vomiting issues connected to taking this drug. [51]

Phenylephrine is pregnancy category C. Due to the lack of studies done in animals and in humans, it is not known whether there is harm to the fetus. Phenylephrine should only be given to pregnant women who have a clear need. [51]

Extended use may cause rhinitis medicamentosa, a condition of rebound nasal congestion. [52]

Interactions

Phenylephrine is susceptible to metabolism by monoamine oxidase. [8] [11] Because of this, monoamine oxidase inhibitors (MAOIs) can inhibit the metabolism of phenylephrine and increase exposure to the medication. [8] [11] Whereas a 45 mg oral dose of phenylephrine alone increases systolic blood pressure by 20 mmHg, use of this dose in people on MAOIs increases systolic blood pressure by more than 60 mmHg. [11]

Phenylephrine can interact with other adrenergic drugs, such as beta blockers like propranolol, α1-adrenergic receptor antagonists like chlorpromazine, α2-adrenergic receptor agonists like clonidine, norepinephrine reuptake inhibitors like atomoxetine and amitriptyline, and MAOIs (which increase norepinephrine levels). [5] It can also interact with corticosteroids like prednisone, which sensitize the vasculature to sympathomimetics and augment their vasoconstrictive effects, and with ergot alkaloids, which also have vasoconstrictor effects and can have additive or synergistic effects with phenylephrine. [5] In addition, combination of phenylephrine with other sympathomimetic drugs can increase pressor effects and the risk of hemorrhagic stroke. [5] Other drugs that may decrease the effects of phenylephrine may include calcium channel blockers, ACE inhibitors and benzodiazepines. [53] Patients taking these medications may need a higher dose of phenylephrine to achieve a comparable increase in blood pressure. [53] Concomitant use of phenylephrine with the preceding agents may necessitate dose adjustments.

Acetaminophen (paracetamol) has been found to increase exposure to oral phenylephrine. [11] It more than doubles phenylephrine's bioavailability, reduces its absorption half-time by 50%, increases phenylephrine levels by approximately 2-fold, and increases peak phenylephrine levels by 4-fold, with substantial interindividual variability. [11] Phenylephrine is widely formulated with acetaminophen in combination products. [11] The combination may increase the cardiovascular effects of phenylephrine. [11] The mechanism of the interaction between phenylephrine and acetaminophen is unknown, but it has been suggested that it may be due to saturation of sulfation pathways by acetaminophen that also participate in phenylephrine metabolism. [11]

Pharmacology

Pharmacodynamics

Phenylephrine is a selective agonist of the α1-adrenergic receptor, one of the biological targets of the catecholamine hormones and neurotransmitters epinephrine (adrenaline) and norepinephrine (noradrenaline). [8] [5] [15] It is a full agonist of the α1-adrenergic receptor in most assessed tissues. [54] The drug has weak, minimal, or no agonist activity at the α2-adrenergic receptor or the β-adrenergic receptors. [8] [5] [15] At the β-adrenergic receptors, it is a partial agonist. [54]

Phenylephrine also has relatively little or no activity as a norepinephrine releasing agent. [8] [15] As such, it has little activity as an indirectly acting sympathomimetic and non-selective activator of adrenergic receptors. [8] [15] This is in contrast to related sympathomimetics like pseudoephedrine. [8] However, more recent research suggests that phenylephrine may actually be more potent as a norepinephrine releasing agent than has previously been thought. [55] This might help to explain certain unexpected pharmacodynamic effects of the drug. [55]

Because of its α1-adrenergic receptor agonism, phenylephrine is a directly acting sympathomimetic vasoconstrictor [8] [15] and produces both venous and arterial vasoconstriction. [49] [5] The term sympathomimetic means that it mimics the actions of epinephrine or norepinephrine. [56]

Phenylephrine works as a nasal decongestant by causing local vasoconstriction in the nose. [15] Whereas the related sympathomimetic decongestant pseudoephedrine causes both vasoconstriction and increase of mucociliary clearance through its non-specific adrenergic activity, phenylephrine's selective α1-adrenergic receptor agonism causes vasoconstriction alone, resulting in a difference in their methods of action.[ citation needed ]

Pharmacokinetics

Absorption

Phenylephrine is rapidly absorbed from the gastrointestinal tract when taken orally. [8] However, its absorption is incomplete and erratic. [9] Because of extensive first-pass metabolism, phenylephrine has an oral bioavailability of only about 38% relative to intravenous administration. [8] [3] [9] [10] However, another source has stated that the bioavailability of phenylephrine is poorly documented and may actually be as low as 0.003%. [11] The time to peak concentrations is 1.0 to 1.3 hours. [8]

Distribution

The steady-state volume of distribution of phenylephrine is 340 L. [5]

Phenylephrine does not cross the blood–brain barrier and hence is a peripherally selective drug with no central nervous system activity. [40] [41] [8] [15] Its lack of blood-brain barrier permeability is related to its hydroxyl groups and high hydrophilicity. [8] [46] The lack of central permeation with phenylephrine is in contrast to certain other related decongestant and sympathomimetic agents like pseudoephedrine, ephedrine, and phenylpropanolamine. [46] [8] [15]

Metabolism

Phenylephrine is metabolized in the intestines and liver prior to reaching the systemic circulation when taken orally. [8] It is extensively metabolized during first-pass metabolism due to susceptibility to monoamine oxidases, similarly to epinephrine. [8] [5] [3] [9] Phenylephrine is metabolized via oxidative deamination by both MAO-A and MAO-B. [5] [3] [9] In contrast to epinephrine and norepinephrine, phenylephrine is not a catecholamine, and is not metabolized by catechol O-methyltransferase (COMT). [15] Besides monoamine oxidase, phenylephrine is also metabolized by sulfation and glucuronidation conjugation. [5] [3] Non-oral routes of phenylephrine, like intranasal, ophthalmic, and parenteral, do not undergo first-pass metabolism in the gastrointestinal tract. [9]

The major metabolite of phenylephrine is meta-hydroxymandelic acid, which is inactive. [3] [9] Lesser metabolites of phenylephrine include sulfate and glucuronide conjugates, which are also inactive. [3] [9]

Unlike phenylephrine, related sympathomimetics with a methyl group at the α carbon (i.e., amphetamines), like ephedrine, pseudoephedrine, phenylpropanolamine, methoxamine, and methoxyphenamine, are resistant to degradation by monoamine oxidase. [9]

Elimination

Phenylephrine is primarily excreted in urine. [5] [3] It is recovered 86% in urine. [3] The drug is excreted in urine 3 to 16% unchanged, 57% as meta-hydroxymandelic acid, and 8% as sulfate conjugates. [8] [3] Glucuronide conjugates constitute a smaller portion of phenylephrine. [9]

Phenylephrine has a relatively short elimination half-life of 2.0 to 3.0 hours regardless of route of administration. [8] [5] [3] [13] [9] Its lack of metabolism by COMT is said to be responsible for its much longer duration of action than related agents like norepinephrine. [15]

Chemistry

Phenylephrine is a substituted phenethylamine and can also be referred to structurally as (R)-β,3-dihydroxy-N-methylphenethylamine. [1] [57] [3] It is closely structurally related to epinephrine (adrenaline; 3,4,β-trihydroxy-N-methylphenethylamine), differing from it only in the absence of one hydroxyl group on the phenyl ring. [8] It is a chiral compound and is used as the enantiopure (R)-stereoisomer. [13] [1] The racemic form has not been formally named or used. [1]

Phenylephrine is the N-methylated derivative of norfenefrine (3,β-dihydroxyphenethylamine). [1] The racemic N-ethyl analogue is etilefrine (ethylphenephrine). [1] Synephrine (p-synephrine, oxedrine; 4,β-dihydroxyphenethylamine) is a positional isomer of phenylephrine. [56] In contrast to epinephrine and norepinephrine (noradrenaline; 3,4,β-trihydroxyphenethylamine), phenylephrine is not a catecholamine since it does not have two hydroxyl groups on its phenyl ring. [15] Besides the catecholamines, the chemical structure of phenylephrine somewhat resembles that of amphetamine (α-methylphenethylamine). [46] However, phenylephrine does not have a methyl group at the α carbon and hence is not an amphetamine itself. [46]

Phenylephrine is a small-molecule compound with the molecular formula C9H13NO2 and a molecular weight of 167.205 g/mol. [57] [3] It is a highly hydrophilic compound, with an experimental log P of -0.3. [58] [57] [3] Phenylephrine is used medically almost always as the hydrochloride salt. [2] [1] However, the free base form and the tannate salt have also been used pharmaceutically to a much lesser extent. [2]

Pivenfrine is the 3-pivalate ester of phenylephrine and has much greater lipophilicity in comparison. [1] [59]

History

Phenylephrine was first patented in 1927 and was first introduced for medical use in 1938. [60]

Society and culture

Names

Phenylephrine is the generic name of the drug and its INN Tooltip International Nonproprietary Name, BAN Tooltip British Approved Name, and DCF Tooltip Dénomination Commune Française, while its USAN Tooltip United States Adopted Name and BANM Tooltip British Approved Name in the case of the hydrochloride salt are phenylephrine hydrochloride. [1] [2] [61] [4] Synonyms of phenylephrine include phenephrine, fenefrine, L-m-synephrine, metaoxedrine, neo-oxedrine, mesatonum, neosynephrine, and m-sympatol. [1] [2] [4] Brand names of phenylephrine include Neosynephrine or Neo-Synephrine and Sudafed PE, among numerous others. [1] [2] [3] [4]

Availability

Phenylephrine is available worldwide as a prescription drug in many different formulations. [4]

Related Research Articles

<span class="mw-page-title-main">Pseudoephedrine</span> Pharmaceutical drug

Pseudoephedrine, sold under the brand name Sudafed among others, is a sympathomimetic medication which is used as a decongestant to treat nasal congestion. It has also been used off-label for certain other indications, like treatment of low blood pressure. At higher doses, it may produce various additional effects including stimulant, appetite suppressant, and performance-enhancing effects. In relation to this, non-medical use of pseudoephedrine has been encountered. The medication is taken by mouth.

<span class="mw-page-title-main">Ephedrine</span> Medication and stimulant

Ephedrine is a central nervous system (CNS) stimulant and sympathomimetic agent that is often used to prevent low blood pressure during anesthesia. It has also been used for asthma, narcolepsy, and obesity but is not the preferred treatment. It is of unclear benefit in nasal congestion. It can be taken by mouth or by injection into a muscle, vein, or just under the skin. Onset with intravenous use is fast, while injection into a muscle can take 20 minutes, and by mouth can take an hour for effect. When given by injection, it lasts about an hour, and when taken by mouth, it can last up to four hours.

<span class="mw-page-title-main">Xylometazoline</span> Nasal decongestant

Xylometazoline, also spelled xylomethazoline, is a medication used to reduce symptoms of nasal congestion, allergic rhinitis, and sinusitis. It is used directly in the nose as a spray or drops.

<span class="mw-page-title-main">Vasoconstriction</span> Narrowing of blood vessels due to the constriction of smooth muscle cells

Vasoconstriction is the narrowing of the blood vessels resulting from contraction of the muscular wall of the vessels, in particular the large arteries and small arterioles. The process is the opposite of vasodilation, the widening of blood vessels. The process is particularly important in controlling hemorrhage and reducing acute blood loss. When blood vessels constrict, the flow of blood is restricted or decreased, thus retaining body heat or increasing vascular resistance. This makes the skin turn paler because less blood reaches the surface, reducing the radiation of heat. On a larger level, vasoconstriction is one mechanism by which the body regulates and maintains mean arterial pressure.

A decongestant, or nasal decongestant, is a type of pharmaceutical drug that is used to relieve nasal congestion in the upper respiratory tract. The active ingredient in most decongestants is either pseudoephedrine or phenylephrine. Intranasal corticosteroids can also be used as decongestants and antihistamines can be used to alleviate runny nose, nasal itch, and sneezing.

<span class="mw-page-title-main">Phenylpropanolamine</span> Sympathomimetic agent

Phenylpropanolamine (PPA), sold under many brand names, is a sympathomimetic agent which is used as a decongestant and appetite suppressant. It was previously commonly used in prescription and over-the-counter cough and cold preparations. The medication is taken by mouth.

<span class="mw-page-title-main">Sympathomimetic drug</span> Substance that mimics effects of catecholamines

Sympathomimetic drugs are stimulant compounds which mimic the effects of endogenous agonists of the sympathetic nervous system. Examples of sympathomimetic effects include increases in heart rate, force of cardiac contraction, and blood pressure. The primary endogenous agonists of the sympathetic nervous system are the catecholamines, which function as both neurotransmitters and hormones. Sympathomimetic drugs are used to treat cardiac arrest and low blood pressure, or even delay premature labor, among other things.

<span class="mw-page-title-main">Oxymetazoline</span> Topical decongestant

Oxymetazoline, sold under the brand name Afrin among others, is a topical decongestant and vasoconstrictor medication. It is available over-the-counter as a nasal spray to treat nasal congestion and nosebleeds, as eye drops to treat eye redness due to minor irritation, and as a prescription topical cream to treat persistent facial redness due to rosacea in adults. Its effects begin within minutes and last for up to six hours. Intranasal use for longer than three to five days may cause congestion to recur or worsen, resulting in physical dependence.

An adrenergic agonist is a drug that stimulates a response from the adrenergic receptors. The five main categories of adrenergic receptors are: α1, α2, β1, β2, and β3, although there are more subtypes, and agonists vary in specificity between these receptors, and may be classified respectively. However, there are also other mechanisms of adrenergic agonism. Epinephrine and norepinephrine are endogenous and broad-spectrum. More selective agonists are more useful in pharmacology.

<span class="mw-page-title-main">Synephrine</span> Chemical compound

Synephrine, or, more specifically, p-synephrine, is an alkaloid, occurring naturally in some plants and animals, and also in approved drugs products as its m-substituted analog known as neo-synephrine. p-Synephrine and m-synephrine are known for their longer acting adrenergic effects compared to epinephrine and norepinephrine. This substance is present at very low concentrations in common foodstuffs such as orange juice and other orange products, both of the "sweet" and "bitter" variety. The preparations used in traditional Chinese medicine (TCM), also known as Zhi Shi (枳实), are the immature and dried whole oranges from Citrus aurantium. Extracts of the same material or purified synephrine are also marketed in the US, sometimes in combination with caffeine, as a weight-loss-promoting dietary supplement for oral consumption. While the traditional preparations have been in use for millennia as a component of TCM-formulas, synephrine itself is not an approved over the counter drug. As a pharmaceutical, m-synephrine (phenylephrine) is still used as a sympathomimetic, mostly by injection for the treatment of emergencies such as shock, and rarely orally for the treatment of bronchial problems associated with asthma and hay-fever.

<span class="mw-page-title-main">Naphazoline</span> Chemical compound

Naphazoline is a medicine used as a decongestant, and a vasoconstrictor added to eye drops to relieve red eye. It has a rapid action in reducing swelling when applied to mucous membranes. It is a sympathomimetic agent with marked alpha adrenergic activity that acts on alpha-receptors in the arterioles of the conjunctiva to produce constriction, resulting in decreased congestion.

<span class="mw-page-title-main">Isoprenaline</span> Medication for slow heart rate

Isoprenaline, also known as isoproterenol and sold under the brand name Isuprel among others, is a sympathomimetic medication which is used in the treatment of acute bradycardia, heart block, and rarely for asthma, among other indications. It is used by injection into a vein, muscle, fat, or the heart, by inhalation, and in the past under the tongue or into the rectum.

<span class="mw-page-title-main">Rhinitis medicamentosa</span> Medical condition

Rhinitis medicamentosa is a condition of rebound nasal congestion suspected to be brought on by extended use of topical decongestants and certain oral medications that constrict blood vessels in the lining of the nose, although evidence has been contradictory.

<span class="mw-page-title-main">Phentolamine</span> An α-adrenergic antagonist medication

Phentolamine, sold under the brand name Regitine among others, is a reversible nonselective α-adrenergic antagonist.

<span class="mw-page-title-main">Labetalol</span> Medication used to treat high blood pressure

Labetalol is a medication used to treat high blood pressure and in long term management of angina. This includes essential hypertension, hypertensive emergencies, and hypertension of pregnancy. In essential hypertension it is generally less preferred than a number of other blood pressure medications. It can be given by mouth or by injection into a vein.

<span class="mw-page-title-main">Alpha-adrenergic agonist</span> Class of drugs

Alpha-adrenergic agonists are a class of sympathomimetic agents that selectively stimulates alpha adrenergic receptors. The alpha-adrenergic receptor has two subclasses α1 and α2. Alpha 2 receptors are associated with sympatholytic properties. Alpha-adrenergic agonists have the opposite function of alpha blockers. Alpha adrenoreceptor ligands mimic the action of epinephrine and norepinephrine signaling in the heart, smooth muscle and central nervous system, with norepinephrine being the highest affinity. The activation of α1 stimulates the membrane bound enzyme phospholipase C, and activation of α2 inhibits the enzyme adenylate cyclase. Inactivation of adenylate cyclase in turn leads to the inactivation of the secondary messenger cyclic adenosine monophosphate and induces smooth muscle and blood vessel constriction.

<span class="mw-page-title-main">Etilefrine</span> Chemical compound

Etilefrine, sold under the brand name Effortil among others, is a sympathomimetic medication used as an antihypotensive agent to treat orthostatic hypotension. It is usually used by mouth, but is also available as an injectable.

A cardiac stimulant is a drug which acts as a stimulant of the heart – e.g., via positive chronotropic action and/or inotropic action. They increase cardiac output.

β1-Adrenergic receptor agonists, also known as beta-1 agonists, are a class of drugs that bind selectively to the β1-adrenergic receptor. As a result, they act more selectively upon the heart. β-Adrenoceptors typically bind to norepinephrine release by sympathetic adrenergic nerves and to circulating epinephrine. The effect of β-adrenoceptors is cardiac stimulation, such as increased heart rate, heart contractility, heart conduction velocity, and heart relaxation.

Peripherally selective drugs have their primary mechanism of action outside of the central nervous system (CNS), usually because they are excluded from the CNS by the blood–brain barrier. By being excluded from the CNS, drugs may act on the rest of the body without producing side-effects related to their effects on the brain or spinal cord. For example, most opioids cause sedation when given at a sufficiently high dose, but peripherally selective opioids can act on the rest of the body without entering the brain and are less likely to cause sedation. These peripherally selective opioids can be used as antidiarrheals, for instance loperamide (Imodium).

References

  1. 1 2 3 4 5 6 7 8 9 10 11 12 Elks J (2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer US. pp. 61, 1001. ISBN   978-1-4757-2085-3 . Retrieved 22 July 2024.
  2. 1 2 3 4 5 6 7 Schweizerischer Apotheker-Verein (2000). Index Nominum 2000: International Drug Directory. Medpharm Scientific Publishers. p. 826. ISBN   978-3-88763-075-1 . Retrieved 22 July 2024.
  3. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 "Phenylephrine: Uses, Interactions, Mechanism of Action". DrugBank Online. 25 November 2022. Retrieved 21 July 2024.
  4. 1 2 3 4 5 6 "Phenylephrine (International database)". Drugs.com. 7 July 2024. Retrieved 22 July 2024.
  5. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 Richards E, Lopez MJ, Maani CV (2023). "Phenylephrine". StatPearls. Treasure Island, Florida: StatPearls Publishing. PMID   30521222 . Retrieved 27 April 2023.
  6. 1 2 3 4 5 6 7 "Drugs@FDA: FDA-Approved Drugs". accessdata.fda.gov. Food and Drug Administration. Retrieved 21 July 2024.
  7. 1 2 3 4 5 "Search Results for phenylephrine". DailyMed. Retrieved 21 July 2024.
  8. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 Eccles R (January 2007). "Substitution of phenylephrine for pseudoephedrine as a nasal decongeststant. An illogical way to control methamphetamine abuse". Br J Clin Pharmacol. 63 (1): 10–14. doi:10.1111/j.1365-2125.2006.02833.x. PMC   2000711 . PMID   17116124. PE and PDE are sympathomimetic vasoconstrictors that are closely related to adrenaline in structure, as illustrated in Figure 1. PE differs chemically from adrenaline only in the absence of one hydroxyl group from the benzene ring. [...] PE is a relatively selective α1 agonist. It has weak α2 adrenoceptor agonist activity and low β agonist activity. Most of the α1 agonist activity is due to a direct action on α receptors with relatively little indirect effect via noradrenaline release [11].
  9. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 Chua SS, Benrimoj SI, Triggs EJ (1989). "Pharmacokinetics of non-prescription sympathomimetic agents". Biopharm Drug Dispos. 10 (1): 1–14. doi:10.1002/bdd.2510100102. PMID   2647163.
  10. 1 2 "Recommendation on phenylephrine". Medsafe. 23 May 2013 [25 November 2004]. Retrieved 25 April 2023.
  11. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 Atkinson HC, Potts AL, Anderson BJ (August 2015). "Potential cardiovascular adverse events when phenylephrine is combined with paracetamol: simulation and narrative review". Eur J Clin Pharmacol. 71 (8): 931–938. doi:10.1007/s00228-015-1876-1. PMC   4500855 . PMID   26022219.
  12. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 "Phenylephrine Monograph for Professionals". Drugs.com. AHFS. 2 March 2022. Retrieved 9 May 2022. However, efficacy of oral phenylephrine for this use [as a decongestant] has been questioned.
  13. 1 2 3 Kanfer I, Dowse R, Vuma V (1993). "Pharmacokinetics of oral decongestants". Pharmacotherapy. 13 (6 Pt 2): 116S–128S, discussion 143S–146S. doi:10.1002/j.1875-9114.1993.tb02780.x. PMID   7507589. S2CID   23528004.
  14. 1 2 3 Joint Formulary Committee (2018). BNF 76 : September 2018 - March 2019. London: British Medical Association, Royal Pharmaceutical Society of Great Britain. pp. 188–189. ISBN   9780857113382. OCLC   1021215075.
  15. 1 2 3 4 5 6 7 8 9 10 11 12 O'Donnell SR (March 1995). "Sympathomimetic vasoconstrictors as nasal decongestants". Med J Aust. 162 (5): 264–267. doi:10.5694/j.1326-5377.1995.tb139882.x. PMID   7534374.
  16. ↑ U.S. patent 1,932,347 , application 1928, expired 1950
  17. ↑ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 541. ISBN   9783527607495.
  18. ↑ "Competitive Generic Therapy Approvals". U.S. Food and Drug Administration (FDA). 29 June 2023. Archived from the original on 29 June 2023. Retrieved 29 June 2023.
  19. ↑ "First Generic Drug Approvals 2023". U.S. Food and Drug Administration (FDA). 30 May 2023. Archived from the original on 30 June 2023. Retrieved 30 June 2023.
  20. ↑ "Max Strength Decongestant Tablets" (PDF). www.mhra.gov.uk. p. 10. Archived from the original (PDF) on 19 August 2019. Retrieved 10 January 2019.
  21. ↑ Hatton RC, Hendeles L (March 2022). "Why Is Oral Phenylephrine on the Market After Compelling Evidence of Its Ineffectiveness as a Decongestant?". Ann Pharmacother. 56 (11): 1275–1278. doi:10.1177/10600280221081526. PMID   35337187. S2CID   247712448.
  22. ↑ Lowe D (March 2022). "The Uselessness of Phenylephrine". Science (blog).
  23. 1 2 Christensen J (12 September 2023). "Popular OTC medicines for colds and allergies don't work, FDA panel says". CNN. Retrieved 12 September 2023.
  24. 1 2 "FDA Proposes Ending Use of Oral Phenylephrine as OTC Monograph Nasal Decongestant Active Ingredient After Extensive Review". U.S. Food and Drug Administration (FDA) (Press release). 7 November 2024. Retrieved 10 November 2024.
  25. ↑ Presley B, Bianchi B, Coleman J, Diamond F, McNally G (July 2018). "Efficiency of extraction and conversion of pseudoephedrine to methamphetamine from tamper-resistant and non-tamper-resistant formulations". Journal of Pharmaceutical and Biomedical Analysis. 156: 16–22. doi: 10.1016/j.jpba.2018.04.016 . PMID   29684907. S2CID   13660478.
  26. 1 2 Horak F, Zieglmayer P, Zieglmayer R, Lemell P, Yao R, Staudinger H, et al. (February 2009). "A placebo-controlled study of the nasal decongestant effect of phenylephrine and pseudoephedrine in the Vienna Challenge Chamber". Annals of Allergy, Asthma & Immunology. 102 (2): 116–20. doi:10.1016/S1081-1206(10)60240-2. PMID   19230461. Phenylephrine was not significantly different from placebo in the primary end point.
  27. 1 2 Day JH, Briscoe MP, Ratz JD, Danzig M, Yao R (April 2009). "Efficacy of loratadine-montelukast on nasal congestion in patients with seasonal allergic rhinitis in an environmental exposure unit". Annals of Allergy, Asthma & Immunology. 102 (4): 328–38. doi:10.1016/S1081-1206(10)60339-0. PMID   19441605. There were no statistically significant differences between phenylephrine and placebo for any measures.
  28. ↑ Hendeles L, Hatton RC (July 2006). "Oral phenylephrine: an ineffective replacement for pseudoephedrine?". The Journal of Allergy and Clinical Immunology. 118 (1): 279–80. doi: 10.1016/j.jaci.2006.03.002 . PMID   16815167.
  29. ↑ Hatton RC, Winterstein AG, McKelvey RP, Shuster J, Hendeles L (March 2007). "Efficacy and safety of oral phenylephrine: systematic review and meta-analysis". The Annals of Pharmacotherapy. 41 (3): 381–90. doi:10.1345/aph.1H679. PMID   17264159. S2CID   25627664. Archived from the original (abstract) on 27 February 2007.(published online Jan 2007)
  30. ↑ Kollar C, Schneider H, Waksman J, Krusinska E (June 2007). "Meta-analysis of the efficacy of a single dose of phenylephrine 10 mg compared with placebo in adults with acute nasal congestion due to the common cold". Clinical Therapeutics. 29 (6): 1057–70. doi:10.1016/j.clinthera.2007.05.021. PMID   17692721.
  31. ↑ Desjardins PJ, Berlin RG (October 2007). "Efficacy of phenylephrine". British Journal of Clinical Pharmacology. 64 (4): 555–6, author reply 557. doi:10.1111/j.1365-2125.2007.02935.x. PMC   2048561 . PMID   17610531.
  32. ↑ Hillenmeyer K (30 January 2007). "All stuffed up: Reformulated cold medicines might not be able to do the job". Sarasota Herald-Tribune . Archived from the original on 1 March 2007. Retrieved 25 April 2023.
  33. ↑ "FDA clarifies results of recent AC meeting on oral phenylephrine". U.S. Food and Drug Administration (FDA). 14 September 2023. Retrieved 14 September 2023.
  34. ↑ Constantino AK (12 September 2023). "Decongestant found in many cold, allergy medicines doesn't actually work, FDA advisors say". CNBC. Retrieved 12 September 2023.
  35. ↑ "Hemorrhoids". Mayo Clinic.
  36. ↑ "Phenylephrine HCl Suppository". WebMD. Retrieved 4 April 2015.
  37. ↑ "Preparation H – cocoa butter and phenylephrine hydrochloride suppository". DailyMed. U.S. National Institutes of Health. Retrieved 4 April 2015.
  38. ↑ "Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% — Sterile" (PDF). Akorn. Archived from the original (PDF) on 3 March 2016.
  39. ↑ Bizrah M, Corbett MC (March 2019). "Intracameral Phenylephrine to Arrest Intraoperative Intraocular Bleeding: A New Technique". Ophthalmology and Therapy. 8 (1): 137–141. doi:10.1007/s40123-019-0165-y. PMC   6393249 . PMID   30771215.
  40. 1 2 3 4 5 6 7 8 9 Meng L, Sun Y, Zhao X, Meng DM, Liu Z, Adams DC, et al. (January 2024). "Effects of phenylephrine on systemic and cerebral circulations in humans: a systematic review with mechanistic explanations". Anaesthesia. 79 (1): 71–85. doi: 10.1111/anae.16172 . PMID   37948131.
  41. 1 2 3 4 5 6 Larson S, Anderson L, Thomson S (January 2021). "Effect of phenylephrine on cerebral oxygen saturation and cardiac output in adults when used to treat intraoperative hypotension: a systematic review". JBI Evid Synth. 19 (1): 34–58. doi:10.11124/JBISRIR-D-19-00352. PMID   32941358.
  42. ↑ Cooper BE (2008). "Review and update on inotropes and vasopressors". AACN Advanced Critical Care. 19 (1): 5–13, quiz 14–15. doi:10.1097/01.AACN.0000310743.32298.1d. PMID   18418098. S2CID   39192378.
  43. 1 2 3 4 5 Lyonga Ngonge A, Nyange C, Ghali JK (February 2024). "Novel pharmacotherapeutic options for the treatment of postural orthostatic tachycardia syndrome". Expert Opin Pharmacother. 25 (2): 181–188. doi:10.1080/14656566.2024.2319224. PMID   38465412.
  44. ↑ Jiang P, Christakos A, Fam M, Sadeghi-Nejad H (October 2014). "Prophylactic phenylephrine for iatrogenic priapism: a pilot study with Peyronie's patients". Korean J Urol. 55 (10): 665–669. doi:10.4111/kju.2014.55.10.665. PMC   4198766 . PMID   25324950.
  45. ↑ Martin C, Cocchio C (February 2016). "Effect of phenylephrine and terbutaline on ischemic priapism: a retrospective review". Am J Emerg Med. 34 (2): 222–224. doi:10.1016/j.ajem.2015.10.029. PMID   26597497.
  46. 1 2 3 4 5 Johnson DA, Hricik JG (1993). "The pharmacology of α-adrenergic decongestants". Pharmacotherapy. 13 (6 Pt 2): 110S–115S, discussion 143S–146S. doi:10.1002/j.1875-9114.1993.tb02779.x. PMID   7507588.
  47. ↑ "Phenylephrine (Rx)". Medscape. Retrieved 4 April 2015.
  48. ↑ Stavert B, McGuinness MB, Harper CA, Guymer RH, Finger RP (June 2015). "Cardiovascular Adverse Effects of Phenylephrine Eyedrops: A Systematic Review and Meta-analysis". JAMA Ophthalmology. 133 (6): 647–652. doi: 10.1001/jamaophthalmol.2015.0325 . PMID   25789577.
  49. 1 2 "Phenylephrine hydrochloride injection". DailyMed. U.S. National Institutes of Health. Retrieved 4 April 2015.
  50. ↑ Shen H (2008). Illustrated Pharmacology Memory Cards: PharMnemonics. Minireview. p. 3. ISBN   978-1-59541-101-3.
  51. 1 2 "Phenylephrine Hydrochloride injection, for intravenous use" (PDF). U.S. Food and Drug Administration.
  52. ↑ "Neo-Synephrine Nasal Spray Drug Information, Professional". drugs.com. Archived from the original on 11 May 2015. Retrieved 4 April 2015.
  53. 1 2 "Vazculep Package Insert" (PDF). U.S. Food and Drug Administration.
  54. 1 2 Chess-Williams RG, Williamson KL, Broadley KJ (1990). "Whether phenylephrine exerts inotropic effects through alpha- or beta-adrenoceptors depends upon the relative receptor populations". Fundam Clin Pharmacol. 4 (1): 25–37. doi:10.1111/j.1472-8206.1990.tb01014.x. PMID   2160415.
  55. 1 2 Al-Khrasani M, Karadi DA, Galambos AR, Sperlagh B, Vizi ES (November 2022). "The Pharmacological Effects of Phenylephrine are Indirect, Mediated by Noradrenaline Release from the Cytoplasm". Neurochem Res. 47 (11): 3272–3284. doi:10.1007/s11064-022-03681-2. PMC   9546997 . PMID   35945308.
  56. 1 2 Costa VM, Grando LG, Milandri E, Nardi J, Teixeira P, Mladěnka P, et al. (November 2022). "Natural Sympathomimetic Drugs: From Pharmacology to Toxicology". Biomolecules. 12 (12): 1793. doi: 10.3390/biom12121793 . PMC   9775352 . PMID   36551221.
  57. 1 2 3 "Phenylephrine". PubChem. Retrieved 21 July 2024.
  58. ↑ Xiao K (2020). Analytical Scientists in Pharmaceutical Product Development: Task Management and Practical Knowledge. Wiley. p. 122. ISBN   978-1-119-54782-2 . Retrieved 21 July 2024. Second, having multiple polar groups on its molecular structure makes phenylephrine like to interact with water molecules as well. Indeed, the log P (Octanol/Water Partition Coefficient) value of phenylephrine is —0.3, which shows the strong hydrophilicity of this molecule.
  59. ↑ "Pivenfrine". PubChem. Retrieved 1 September 2024.
  60. ↑ Deol N, Alvarez G, Elrabi O, Chen G, Ferraro N (December 2023). "A comparative review of epinephrine and phenylephrine as vasoconstrictors in dental anesthesia: exploring the factors behind epinephrine's prevalence in the US". J Dent Anesth Pain Med. 23 (6): 293–302. doi:10.17245/jdapm.2023.23.6.293. PMC   10703557 . PMID   38076507. Phenylephrine, a synthetic selective alpha-1 adrenergic agonist, first received its patent in 1927 and was introduced for medical use in 1938 [8].
  61. ↑ Morton IK, Hall JM (2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Netherlands. p. 219. ISBN   978-94-011-4439-1 . Retrieved 22 July 2024.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.